Ebola

Featured Article

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

First-hand accounts of the care that was delivered during the 2013-16 West African outbreak of Ebola virus disease provided impetus for these guidelines.

Latest News

Thirteen Confirmed Ebola Cases in Latest Congo Outbreak

Thirteen Confirmed Ebola Cases in Latest Congo Outbreak

The number of confirmed cases in a new Ebola outbreak in Congo has reached 13, including three deaths.

New Ebola Outbreak in the Democratic Republic of Congo

New Ebola Outbreak in the Democratic Republic of Congo

Just a week after being declared Ebola-free, the DRC said that a new outbreak of the deadly virus has killed at least 20 people.

Evidence Exists for Persistence, Transmission of Ebola Virus

Evidence Exists for Persistence, Transmission of Ebola Virus

Outbreak report describes transmission of Ebola virus one year after survival of Ebola virus disease.

WHO: Congo Ebola Outbreak Over

WHO: Congo Ebola Outbreak Over

The latest Ebola outbreak in the Democratic Republic of Congo is over according to the WHO.

Eyes of Ebola Survivors Show Localized Pathological Changes

Eyes of Ebola Survivors Show Localized Pathological Changes

Survivors of Ebola virus disease have localized pathological changes in photoreceptors.

Single-Dose Ebola Vaccine Durable for 1 to 2 Years

Single-Dose Ebola Vaccine Durable for 1 to 2 Years

Study provides new data on the durability of the humoral immune response up to 2 years after single-dose injection with rVSV-ZEBOV vaccine in a population of primarily European ancestry, and additional data on durability at 1 year after vaccination in 2 African populations.

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two vaccines to prevent Ebola virus disease demonstrated immune responses at 1 month.

Ebola Vaccine Long-Term Safety and Antibody Response

Ebola Vaccine Long-Term Safety and Antibody Response

An Ebola virus vaccine, rVSVΔG-ZEBOV-GP, provided 100% protection against Ebola in a prior phase 3 trial. A new study reports long-term safety data and shows that the vaccine induces an antibody response for at least 1 year.

Novel Retinal Abnormality Seen in Ebola Survivors

Novel Retinal Abnormality Seen in Ebola Survivors

A small percentage of Ebola virus survivors have a novel retinal lesion as a result of the disease.

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

The number of suspected Ebola cases in the Democratic Republic of Congo has risen to 37.

Sign Up for Free e-newsletters